

## HR 5435

BRAIN Act of 2021

**Congress:** 117 (2021–2023, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Sep 30, 2021

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (Oct 1, 2021)

**Official Text:** <https://www.congress.gov/bill/117th-congress/house-bill/5435>

### Sponsor

**Name:** Rep. Blumenauer, Earl [D-OR-3]

**Party:** Democratic • **State:** OR • **Chamber:** House

### Cosponsors (6 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Bacon, Don [R-NE-2]	R · NE		Sep 30, 2021
Rep. Pascrell, Bill, Jr. [D-NJ-9]	D · NJ		Sep 30, 2021
Rep. Fitzpatrick, Brian K. [R-PA-1]	R · PA		Dec 9, 2021
Rep. Chu, Judy [D-CA-27]	D · CA		Jan 20, 2022
Rep. Kilmer, Derek [D-WA-6]	D · WA		Jan 20, 2022
Rep. Tonko, Paul [D-NY-20]	D · NY		Feb 2, 2022

### Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Oct 1, 2021

### Subjects & Policy Tags

#### Policy Area:

Health

### Related Bills

No related bills are listed.

## **Bringing Regulatory Advances Into Neuroscience Act of 2021 or the BRAIN Act of 2021**

This bill requires the Food and Drug Administration (FDA) to establish the Neuroscience Center of Excellence.

The center must develop and implement processes to coordinate FDA activities related to a major disease area or areas affecting the brain or central nervous system.

The FDA must also establish and maintain the Neuroscience Translation Working Group to advise the center. If the FDA terminates the center, the working group shall advise the FDA.

### **Actions Timeline**

---

- **Oct 1, 2021:** Referred to the Subcommittee on Health.
- **Sep 30, 2021:** Introduced in House
- **Sep 30, 2021:** Sponsor introductory remarks on measure. (CR E1050)
- **Sep 30, 2021:** Referred to the House Committee on Energy and Commerce.